# Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

> **NCT06922604** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Glofitamab
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Obinutuzumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06922604
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2029-01-02
- **Final completion:** 2029-01-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922604, "Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06922604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*